Human Albumin for Clinical Outcome in Aneurysmal Subarachnoid Hemorrhages

NARecruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
DRUG

Human albumin

Patients in intervention arm will also receive intermittent boluses of 20 percent human albumin (in addition to standard fluid therapy) that will be administered with dosage regimen of 1.25gm/kg of body weight per 24 hours. The maximum total calculated dose/volume of albumin for the patient will be infused @ 34 ml/hour (over 3 hours) and will be divided in 3 boluses, spaced at 8 hours intervals. During intervention period, duration of treatment (7-day study period) will cover the peak period of cerebral vasospasm from day 4th until 10th day. Albumin administration will be tailored according to the targeted values set for euvolemic fluid balance in each patient. Before randomization (within 72 hours post-ictus) and after day-10 (from day 11th-14th, patient will only receive standard fluid therapy.

Trial Locations (1)

Unknown

RECRUITING

Hamad General Hospital, Doha

Sponsors
All Listed Sponsors
lead

Hamad Medical Corporation

INDUSTRY